Thrombolytic therapy is a huge advance in the management of acute myocardial infarction
(AMI). The results of large clinical trials over the past 9 years have unequivocally …

The past 5 years have witnessed an explosion in the amount of published clinical trial data
for the use of intravenous thrombolytic therapy for acute myocardial infarction. This article …

548 EPITOMES-INTERNAL MEDICINE postinfarction failed to improve survival or left
ventricular function or to reduce the incidence of reinfarction compared with conservative …

OBJECTIVE: To review the literature on the use of thrombolytic agents in the
pharmacotherapeutic management of acute myocardial infarction (AMI). DATA SOURCE …

The use of thrombolytic agents in the treatment of acute myocardial infarction is one of the
major developments in the field of cardiology in recent years. The efficacy of this form of …

Strategies for managing acute myocardial infarction (AMI), with a focus on thrombolytics, are
reviewed. Revised guidelines published by the American College of Cardiology and the …

Thrombolytic therapy has reduced the mortality of acute myocardial infarction when
administered in the first 12 hours after its onset. The author reviews the evidence concerning …

It is now clear that intravenous thrombolytic therapy is the treatment of choice in selected
patients with AMI. It is most effective in patients with their first MIs and of greatest benefit, at …

Recombinant tissue-type plasminogen activator (rt-PA), streptokinase (SK), and anisoylated
plasminogen-streptokinase activator complex (APSAC) have salutary effects on mortality …

Preview There is little question that reperfusion therapy with thrombolytic agents benefits
patients who meet the current eligibility requirements and receive therapy shortly after acute …